Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational Accepts healthy volunteers
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease, Movement Disorders
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease
Interventions
NS 2330
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Interventions
This is an observational study.
Other
Lead sponsor
AskBio Inc
Industry
Eligibility
35 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Early Stage Parkinson Disease
Interventions
Pardaprunox, pramipexole, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease
Interventions
pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years to 79 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
32
States / cities
Brimingham, Alabama • Scottsdale, Arizona • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Prodromal Parkinsons Disease
Interventions
[18F] AV-133 PET Imaging
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease
Interventions
RO7486967, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease
Interventions
Placebo, PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Phoenix, Arizona • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease
Interventions
venglustat GZ/SAR402671, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders, Genetic Predisposition
Interventions
Increase of physical activity volume and intensity with the use of a motivational smartphone application
Behavioral
Lead sponsor
Radboud University Medical Center
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease
Interventions
SER-214
Drug
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Hallandale, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease
Interventions
minocycline, creatine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinsons Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
Conditions
Parkinson Disease
Interventions
Placebo, inosine
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced May 22, 2026, 4:49 AM EDT
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
Conditions
Parkinson's Disease
Interventions
CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 22, 2026, 4:49 AM EDT